Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beauty Health (SKIN) Total Liabilities (2020 - 2025)

Beauty Health (SKIN) has disclosed Total Liabilities for 6 consecutive years, with $438.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities fell 31.55% to $438.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $438.0 million, a 31.55% decrease, with the full-year FY2024 number at $633.9 million, down 27.12% from a year prior.
  • Total Liabilities was $438.0 million for Q3 2025 at Beauty Health, up from $433.6 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $1.1 billion in Q3 2021 to a low of -$161.8 million in Q2 2023.
  • A 5-year average of $605.4 million and a median of $642.6 million in 2024 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: soared 275146.35% in 2021, then crashed 118.61% in 2023.
  • Beauty Health's Total Liabilities stood at $916.5 million in 2021, then fell by 8.78% to $836.0 million in 2022, then rose by 4.03% to $869.7 million in 2023, then decreased by 27.12% to $633.9 million in 2024, then crashed by 30.91% to $438.0 million in 2025.
  • Per Business Quant, the three most recent readings for SKIN's Total Liabilities are $438.0 million (Q3 2025), $433.6 million (Q2 2025), and $627.8 million (Q1 2025).